Long-term low-dose acyclovir against varicella-zoster virus reactivation after allogeneic hematopoietic stem cell transplantation

Y. Kanda, S. Mineishi, T. Saito, A. Saito, S. Yamada, M. Ohnishi, A. Chizuka, H. Niiya, K. Suenaga, K. Nakai, T. Takeuchi, A. Makimoto, R. Tanosaki, M. Kami, Y. Tanaka, S. Fujita, T. Watanabe, Y. Kobayashi, K. Tobinai, Y. Takaue

研究成果: Article査読

94 被引用数 (Scopus)

抄録

To evaluate the efficacy of long-term administration of acyclovir as prophylaxis against varicella-zoster virus (VZV) reactivation, we analyzed the medical records of 86 consecutive adult patients who obtained engraftment after allogeneic hematopoietic stem cell transplantation from January 1996 to March 2000. We started long-term low-dose (400 mg/day) oral administration of acyclovir in June 1999, and this was continued until the end of immunosuppressive therapy after transplantation. There was no breakthrough reactivation of VZV in patients receiving acyclovir. Five patients who were receiving cyclosporine or prednisolone developed VZV reactivation after discontinuing acyclovir. With this prophylaxis, the cumulative incidence of VZV reactivation at 1 year after transplantation decreased from 33% to 10% (P = 0.025). On multivariate analysis, the use of long-term acyclovir was identified as a significant independent parameter for the development of VZV reactivation. These findings suggest the efficacy of long-term prophylaxis with low-dose acyclovir. Resumption of acyclovir upon restarting immunosuppressive therapy might be important for the further prevention of VZV reactivation. The benefit of long-term low-dose acyclovir should be confirmed prospectively.

本文言語English
ページ(範囲)689-692
ページ数4
ジャーナルBone Marrow Transplantation
28
7
DOI
出版ステータスPublished - 2001
外部発表はい

ASJC Scopus subject areas

  • 血液学
  • 移植

フィンガープリント

「Long-term low-dose acyclovir against varicella-zoster virus reactivation after allogeneic hematopoietic stem cell transplantation」の研究トピックを掘り下げます。これらがまとまってユニークなフィンガープリントを構成します。

引用スタイル